Last $11.54 USD
Change Today -0.46 / -3.83%
Volume 502.8K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robert Repella R.Ph.,MBA

Executive Vice President of Global Commercial Operations, CSL Ltd.
AgeTotal Calculated CompensationThis person is connected to 29 board members in 1 different organizations across 3 different industries.

See Board Relationships
55--

Background*

Mr. Robert Repella, also known as Bob, R.Ph., MBA. has been Executive Vice President of Global Commercial Operations at CSL Ltd. since joining in July 1, 2014. Mr. Repella is responsible for a variety of global functions including sales, marketing, commercial development and medical affairs. Mr. Repella has over 30 years of commercial experience including biotech and specialty markets. He served as the Chief Commercial Officer and Senior Vice President of Vanda Pharmaceuticals, ...

Read Full Background

Corporate Headquarters*

2200 Pennsylvania Avenue NW
Washington, District Of Columbia 20037

United States

Phone: 202-734-3400
Fax: 202-296-1450

Board Members Memberships*

Director

Education*

Bachelor's Degree
Rutgers, The State University of New Jersey
MBA
Temple University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

There is no Stock Options data available.

Total Compensation*

There is no Total Compensation data available.
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $11.54 USD -0.46

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Flemming Ornskov M.D., MBA, MPHChief Executive Officer, Managing Director and Director
Shire plc
$2.7M
Victor Grifols Roura Chairman, Chief Executive Officer, President, Managing Director and Member of Appointments & Remuneration Committee
Grifols, S.A.
--
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
--
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director and Member of Strategic Operations Committee
Emergent BioSolutions, Inc.
$1.0M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.